ArticleVirology2008
A more precise HIV integration assay designed to detect small differences finds lower levels of integrated DNA in HAART treated patients.
Article in Virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Trial
- Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay.PLoS pathogens · 2013Trial
- HIV-1 virome profiling using HIV-PULSE to guide therapeutic and curative interventions.EBioMedicine · 2026Article
- Clonal dynamics of HIV-infected and uninfected T cells.EBioMedicine · 2026Article
- Q4ddPCR: a flexible, 4-target assay for high-resolution HIV reservoir profiling.Nature communications · 2026Article
- Article
- Article
- HIV Reservoir: How to Measure It?Current HIV/AIDS reports · 2023Review
- HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H.The Journal of antimicrobial chemotherapy · 2022Article
- Retroviral infection of human neurospheres and use of stem Cell EVs to repair cellular damage.Scientific reports · 2022Article
- Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising HumanLife (Basel, Switzerland) · 2021Article
- High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.The Journal of antimicrobial chemotherapy · 2021Article
- Recommendations for measuring HIV reservoir size in cure-directed clinical trials.Nature medicine · 2020Review
- HIV antibodies level as a marker of HIV persistence: the role of hepatitis C virus coinfection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- EBV renders B cells susceptible to HIV-1 in humanized mice.Life science alliance · 2020Article
- Hypoxic microenvironment shapes HIV-1 replication and latency.Communications biology · 2020Article
- A comparative analysis of unintegrated HIV-1 DNA measurement as a potential biomarker of the cellular reservoir in the blood of patients controlling and non-controlling viral replication.Journal of translational medicine · 2020Article
- Measuring the Success of HIV-1 Cure Strategies.Frontiers in cellular and infection microbiology · 2020Review
- Infrequent HIV Infection of Circulating Monocytes during Antiretroviral Therapy.Journal of virology · 2019Article
- Bacterial dynamin-like protein DynA mediates lipid and content mixing.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Many studies report the level of total viral DNA in HIV-infected patients, but few studies report the level of integrated DNA. It is important to measure integrated DNA in HIV-infected patients because the information could shed light on the effectiveness of antiretroviral therapy, especially intensified therapy, when viral loads may remain undetectable. In order to develop an integration assay for patient samples, we enhanced the sensitivity of our prior integration assay. To do this, we exploited a technique that we developed, called repetitive sampling, and optimized reaction conditions for rare event detection, rather than large dynamic range. We also designed our primers to match more conserved regions of HIV. The result is a new, sensitive, quantitative assay that allows us to measure integrated DNA in HIV-infected patients. When we applied our integration assay to patient PBMCs, we found that the use of HAART is associated with reduced levels of integrated DNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.